SCHEMBL3356073

SCHEMBL3356073

Fc1cccc2ocnc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.38
DHODH Q02127 1/20 0.38
PARP1 P09874 1/20 0.35
PIN1 Q13526 2/20 0.35
CTNNB1 P35222 2/20 0.34
WNT3A P56704 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
NOTUM Q6P988 1/20 0.33
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
GAA P10253 2/20 0.32
NPC1 O15118 2/20 0.32
LMNA P02545 2/20 0.32
RAB9A P51151 2/20 0.32
MEN1 O00255 1/20 0.32
PRNP P04156 1/20 0.32
HPGD P15428 1/20 0.32
KMT2A Q03164 1/20 0.32
IDH1 O75874 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1365239 0.77 NR4A2 (0.39) NR4A2DHODHPIN1IDH1EPHB4
SCHEMBL646093 0.74 ALDH1A1 (0.42) PIN1KDM4EALDH1A1GAALMNA
SCHEMBL13857953 0.74 PSMD14 (0.42) NR4A2DHODHPIN1IDH1EPHB4
SCHEMBL1881059 0.74 PIN1 (0.40) NR4A2PARP1PIN1SMN1; SMN2NOTUM
SCHEMBL31597350 0.74 HTR2A (0.33) NR4A2DHODHCTNNB1WNT3A
SCHEMBL288688 0.74 ELANE (0.43) PARP1PIN1KDM4EALDH1A1EPHB4
SCHEMBL926877 0.74 HSD17B10 (0.36) NR4A2DHODHPARP1PIN1SMN1; SMN2
SCHEMBL2005830 0.74 PIN1 (0.40) NR4A2DHODHPIN1CTNNB1WNT3A
SCHEMBL288687 0.74 PIN1 (0.35) NR4A2DHODHPIN1IDH1EPHB4
SCHEMBL17177020 0.74 PIN1 (0.35) NR4A2DHODHPIN1IDH1EPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171437-A1 (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA AGIOS PHARMACEUTICALS, INC. 2025-05-29 US disclosed
WO-2023164233-A1 (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA AGIOS PHARMACEUTICALS, INC. (US) 2023-08-31 WO disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 US disclosed
WO-2019055750-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF Aduro Biotech, Inc. (US) 2019-03-21 WO disclosed
US-20100120839-A1 PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120839-A1 PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION ALOX15, ALOX12, ALOX15B NR4A2 871/4885DHODH 584/4885PARP1 2065/4885
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 NR4A2 2760/4885DHODH 919/4885PARP1 1342/4885
US-20250171437-A1 (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA PAH, BCKDK, PKM NR4A2 4315/4885DHODH 82/4885PARP1 3357/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 NR4A2 2760/4885DHODH 919/4885PARP1 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.